PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-27.70%
G&A reduction while AVXL shows 178.28% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
1234.83%
Other expenses growth above 1.5x AVXL's 169.37%. Michael Burry would check for concerning trends.
115.67%
Operating expenses growth while AVXL reduces costs. John Neff would investigate differences.
115.67%
Total costs growth while AVXL reduces costs. John Neff would investigate differences.
719.71%
Interest expense change of 719.71% while AVXL maintains costs. Bruce Berkowitz would investigate control.
No Data
No Data available this quarter, please select a different quarter.
-115.67%
EBITDA decline while AVXL shows 13.44% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-115.67%
Operating income decline while AVXL shows 19.61% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
115.67%
Other expenses growth while AVXL reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
133.51%
Tax expense growth while AVXL reduces burden. John Neff would investigate differences.
-133.51%
Net income decline while AVXL shows 19.80% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-132.80%
EPS decline while AVXL shows 20.83% growth. Joel Greenblatt would examine position.
-132.80%
Diluted EPS decline while AVXL shows 17.39% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.